Adalimumab Efficacy in Hidradenitis Suppurativa Patients Is Sustained at Least Three Years With Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). J of Skin 2017, 1 (3.1), s128. https://doi.org/10.25251/skin.1.supp.127.